RT Journal Article
SR Electronic
T1 Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 307
OP 317
DO 10.3949/ccjm.90a.22032
VO 90
IS 5
A1 Randol Kennedy
A1 Hussein Awada
A1 Naga Vura
A1 Daniela Ciltea
A1 Michael Morocco
YR 2023
UL http://www.ccjm.org/content/90/5/307.abstract
AB Immune checkpoint inhibitors are used more and more to treat several types of cancer, significantly extending cancer-free survival. However, concerns are growing about their toxic effects, which are many and varied. Endocrinopathies are some of the most frequently reported adverse effects, and thyroid dysfunction is the most common of these. Here, we review the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, possible factors related to toxicity risk, and principles of management.